Concert Pharmaceuticals (CNCE) – Research Analysts’ Recent Ratings Changes

Concert Pharmaceuticals (NASDAQ: CNCE) recently received a number of ratings updates from brokerages and research firms:

  • 10/7/2019 – Concert Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 10/3/2019 – Concert Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $29.00 to $25.00. They now have a “buy” rating on the stock.
  • 10/1/2019 – Concert Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “
  • 9/30/2019 – Concert Pharmaceuticals had its price target lowered by analysts at SunTrust Banks, Inc. from $30.00 to $20.00. They now have a “buy” rating on the stock.
  • 9/30/2019 – Concert Pharmaceuticals had its “buy” rating reaffirmed by analysts at Janney Montgomery Scott. They now have a $10.00 price target on the stock, down previously from $13.00.
  • 9/30/2019 – Concert Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $18.00 price target on the stock, down previously from $29.00.
  • 9/28/2019 – Concert Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/27/2019 – Concert Pharmaceuticals was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $8.00 price target on the stock, down previously from $18.00.
  • 9/12/2019 – Concert Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 9/5/2019 – Concert Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/4/2019 – Concert Pharmaceuticals was given a new $16.00 price target on by analysts at Janney Montgomery Scott. They now have a “buy” rating on the stock.
  • 9/4/2019 – Concert Pharmaceuticals had its price target raised by analysts at Mizuho from $23.00 to $29.00. They now have a “buy” rating on the stock.
  • 9/4/2019 – Concert Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

Shares of NASDAQ:CNCE traded up $0.32 on Tuesday, reaching $6.21. 288,907 shares of the company were exchanged, compared to its average volume of 230,128. Concert Pharmaceuticals Inc has a 1-year low of $5.36 and a 1-year high of $17.83. The company has a current ratio of 19.63, a quick ratio of 19.63 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average of $8.95 and a 200-day moving average of $10.38. The firm has a market cap of $139.47 million, a price-to-earnings ratio of -2.59 and a beta of 0.90.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.14. Concert Pharmaceuticals had a negative net margin of 7,303.34% and a negative return on equity of 49.44%. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.30 million. As a group, analysts forecast that Concert Pharmaceuticals Inc will post -3.45 earnings per share for the current year.

In other Concert Pharmaceuticals news, Director Heek Christi Van acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were acquired at an average cost of $10.84 per share, for a total transaction of $54,200.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $54,200. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Peter Barton Hutt sold 3,539 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $10.31, for a total transaction of $36,487.09. Following the completion of the sale, the director now owns 7,963 shares in the company, valued at $82,098.53. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Quantamental Technologies LLC purchased a new position in Concert Pharmaceuticals in the 2nd quarter valued at about $27,000. Aperio Group LLC purchased a new position in Concert Pharmaceuticals in the 2nd quarter valued at about $43,000. State Board of Administration of Florida Retirement System purchased a new position in Concert Pharmaceuticals in the 2nd quarter valued at about $128,000. Parametric Portfolio Associates LLC lifted its holdings in Concert Pharmaceuticals by 10.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 11,349 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,089 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its holdings in Concert Pharmaceuticals by 64.4% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 14,800 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 5,800 shares in the last quarter. Institutional investors and hedge funds own 70.74% of the company’s stock.

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Read More: Can systematic risk be avoided?

Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.